

Estimating Survival Risk Without LVAD using INTERMACS

To derive survival at 1 and 2 years on medical management / without LVAD or transplant, we used SCAI shock estimates as a close proxy for INTERMACS 1-3 (see. Burgos et. al.). To derive INTERMACS 4-7 at 1 and 2 years, we used a combination of the ROADMAP study and the REVIVAL registry report.

Please see below for citations to the referenced published studies. This work would not have been possible without our longtime physician champion partner, Dr. Jerry Estep, Cleveland Clinic.

References

- Burgos, Lucrecia María, Rocío Consuelo Baro Vila, Fernando Botto, and Mirta Diez. “SCAI Cardiogenic Shock Classification for Predicting In-Hospital and Long-Term Mortality in Acute Heart Failure.” *Journal of the Society for Cardiovascular Angiography & Interventions* 1, no. 6 (November 2022): 100496. <https://doi.org/10.1016/j.jscai.2022.100496>.
- Kittleson, Michelle M., Palak Shah, Anuradha Lala, Rhondalyn C. McLean, Salpy Pamboukian, Douglas A. Horstmanshof, Jennifer Thibodeau, et al. “INTERMACS Profiles and Outcomes of Ambulatory Advanced Heart Failure Patients: A Report from the REVIVAL Registry.” *The Journal of Heart and Lung Transplantation* 39, no. 1 (January 2020): 16–26. <https://doi.org/10.1016/j.healun.2019.08.017>.
- Shah, Keyur B., Randall C. Starling, Joseph G. Rogers, Douglas A. Horstmanshof, James W. Long, Vigneshwar Kasirajan, Josef Stehlik, Joyce Chuang, David J. Farrar, and Jerry D. Estep. “Left Ventricular Assist Devices versus Medical Management in Ambulatory Heart Failure Patients: An Analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP Study.” *The Journal of Heart and Lung Transplantation* 37, no. 6 (June 2018): 706–14. <https://doi.org/10.1016/j.healun.2017.12.003>.